Articles
Articles, updates, and practical notes on peptides.

Your First Peptide Cycle: Planning, Expectations, and What to Actually Decide
After Peptides 101 conceptually, this is the cycle-planning piece. Pick one goal, pick one compound class, set up supplies and baseline, run the protocol with a 4-week reassessment milestone. The mistakes first-cycle users make and the choices they actually have to make, in order.

Blends and Ratio-Based Dosing: Driver Logic and Pitfalls
How ratio-based dosing works in blended vials, with non-prescriptive examples and risk controls.

Coming Off: The Washout Window
What actually happens when you stop a peptide protocol - IGF-1 returning to baseline, GLP-1 appetite rebound, sleep regression, body-comp drift. Per-class washout expectations and the common mistakes that make off-cycles harder than they need to be.

BPC-157 + TB-500: The Synergy Story Beyond the Headlines
Two repair peptides that hit different rate-limiting steps of healing - angiogenesis-and-fibroblast versus cell-migration-and-actin-remodelling. Why the pair works for tendon work and where the synergy thesis stops being clean.

Cold-Chain Reality: What Actually Happens When You Break Fridge Rules
Peptide-by-peptide stability data, the difference between ‘degraded’ and ‘dead’, why the Arrhenius rule of thumb gets it half right, and the excursion-tolerance question every traveller actually asks.

CagriSema and the Pipeline Past Retatrutide
The next-generation incretins: CagriSema (cagrilintide + semaglutide), survodutide (GLP-1/glucagon), MariTide (Amgen, GLP-1/GIP-antagonist), and the amylin angle. What the phase 3 data shows so far and where each fits if it ships.

Cancer Risk and Growth Factors: Real Data, Theoretical Risk, and the Screen That Matters
BPC-157, TB-500, IGF-1 LR3 and GHK-Cu are routine in this catalogue, and they share a question users hand-wave too often: do they cause or accelerate cancer? This article separates angiogenesis from mitogenesis from cell migration, gives the actual evidence per mechanism, and lays out the pre-cycle screen that’s worth doing.

Cycling Strategies: When to Pulse, When to Hold, When to Run Continuous
Three different mechanisms hide behind the word "cycling" - receptor desensitisation, theoretical-risk washouts, and titrate-and-hold dose strategy. This article separates them by peptide class and lays out the on/off patterns that actually map to each.

Bloodwork for Peptide Users: What to Test, When, and Why
A working bloodwork framework for peptide users: baseline panel, per-class follow-up panels (GH axis, GLP-1, healing, melanocortin, IGF-1 LR3, thymosin), timing, and what to do with the numbers.

The GH Axis Playbook: GHRH vs GHRP vs HGH
Mod GRF 1-29, CJC-1295 DAC, Ipamorelin, Tesamorelin, and Somatropin compared head to head on mechanism, pulsatility, cost, and side-effect profile. Ends in a decision tree.